Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension
- PMID: 8664134
- PMCID: PMC2074561
- DOI: 10.1038/bjc.1996.298
Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension
Abstract
Serum bone alkaline phosphatase (BALP), serum carboxy-terminal propeptide of type I procollagen (PICP) and serum bone gla protein (BGP) as markers of bone formation, serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of collagen resorption and fasting molar ratio of urinary calcium to creatinine (CaCr) and serum parathyroid hormone (PTH) were determined in two groups of cancer patients: 48 with advanced or metastatic disease with negative bone scan and 174 with bone metastases categorised as having lytic, mixed or blastic lesions and with more or fewer than or equal to three sites involved. In patients without apparent bone involvement, bone formation markers were rarely elevated. Conversely, serum ICTP was frequently found to be supranormal, showing it to be a non-specific marker for early detection of bone metastases. As expected, values of bone formation markers progressively increased in patients with lytic, mixed and blastic lesions, but ICTP levels did not show any differences according to the types of bone appearances, confirming previous reports of elevated osteoclast activity also in patients with apparent blastic lesions. Serum PTH increased significantly in patients with lytic compared with patients with mixed and blastic appearances, paralleling the bone formation markers, but CaCr showed the opposite pattern. These data are compatible with calcium entrapment in the bone in patients with increased osteoblast activity. This so called 'bone hunger syndrome' is further confirmed by the finding that in the subgroup of blastic appearances CaCr diminished whereas both ICTP and PTH increased according to the extent of tumour load in the bone.
Similar articles
-
Biochemical picture of bone metabolism in breast cancer patients with bone metastases.Anticancer Res. 1995 Nov-Dec;15(6B):2871-5. Anticancer Res. 1995. PMID: 8669881
-
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.Clin Chem. 1999 Aug;45(8 Pt 1):1240-7. Clin Chem. 1999. PMID: 10430790 Clinical Trial.
-
Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.Br J Cancer. 1995 May;71(5):1061-4. doi: 10.1038/bjc.1995.204. Br J Cancer. 1995. PMID: 7734300 Free PMC article.
-
Biochemical markers and skeletal metastases.Cancer. 2000 Jun 15;88(12 Suppl):2919-26. doi: 10.1002/1097-0142(20000615)88:12+<2919::aid-cncr7>3.0.co;2-z. Cancer. 2000. PMID: 10898335 Review.
-
Usefulness of bone formation markers in breast cancer.Int J Biol Markers. 2005 Jul-Sep;20(3):146-55. doi: 10.1177/172460080502000302. Int J Biol Markers. 2005. PMID: 16240842 Review.
Cited by
-
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1114-24. doi: 10.1007/s00259-003-1197-y. Epub 2003 May 22. Eur J Nucl Med Mol Imaging. 2003. PMID: 12761596 Clinical Trial.
-
Background to and management of treatment-related bone loss in prostate cancer.Drugs Aging. 2002;19(12):899-910. doi: 10.2165/00002512-200219120-00002. Drugs Aging. 2002. PMID: 12495366 Review.
-
The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer.J Cancer Res Clin Oncol. 2017 May;143(5):883-894. doi: 10.1007/s00432-017-2346-1. Epub 2017 Feb 8. J Cancer Res Clin Oncol. 2017. PMID: 28180998 Free PMC article.
-
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.J Natl Cancer Inst. 2014 Apr;106(4):dju013. doi: 10.1093/jnci/dju013. Epub 2014 Feb 24. J Natl Cancer Inst. 2014. PMID: 24565955 Free PMC article. Clinical Trial.
-
Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells.BMC Cancer. 2013 Dec 26;13:605. doi: 10.1186/1471-2407-13-605. BMC Cancer. 2013. PMID: 24370273 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous